Welcome to our dedicated page for Solventum Corporation SEC filings (Ticker: SOLV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Solventum Corporation (NYSE: SOLV) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures filed with the U.S. Securities and Exchange Commission. These documents help investors, analysts and other stakeholders understand Solventum’s financial performance, portfolio actions, capital structure and governance as it operates in the medical instruments and supplies sector.
Solventum uses current reports on Form 8-K to disclose a variety of material events. Examples include 8-K filings reporting quarterly financial results, such as third-quarter 2025 earnings, which incorporate press releases detailing segment performance, non-GAAP measures and updated guidance. Other 8-K filings describe material definitive agreements and their completion, such as the transaction agreement and subsequent closing of the sale of certain assets and liabilities related to Solventum’s purification and filtration business to Thermo Fisher Scientific Inc.
Additional 8-K filings cover capital markets and balance sheet activities, including the commencement, upsizing and pricing of cash tender offers for specified series of senior notes, and an underwriting agreement relating to the sale of shares by a selling shareholder. Governance and leadership changes, such as the appointment of a Chief Commercial Officer and the departure of a segment leader, are also reported on Form 8-K, along with information about related compensation and severance arrangements.
On Stock Titan, users can review these filings alongside AI-powered summaries that explain key points in clear language. This includes highlighting where Solventum discusses its “Transform for the Future” initiative, outlines risk factors, or provides pro forma financial information related to divestitures. The filings page is also a resource for tracking Solventum’s capital allocation strategy, including debt reduction, note tender offers and the authorization of a share repurchase program, as disclosed in its official documents.
WEILAND JOHN H reported acquisition or exercise transactions in this Form 4 filing.
Solventum Corp director John H. Weiland received a grant of 3,300 Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive 1 share of Solventum common stock upon settlement. The RSUs will fully vest on May 15, 2027, if he continues serving through that date.
Wendell Amy McBride reported acquisition or exercise transactions in this Form 4 filing.
Solventum Corp director Wendell Amy McBride received a grant of 3,300 restricted stock units as equity compensation. Each RSU represents a contingent right to receive 1 share of Solventum common stock upon settlement. The award vests in full on May 15, 2027, subject to continued service. Following this grant, McBride holds 3,300 RSUs directly.
Solventum Corp director Darryl L. Wilson received a grant of 3,300 Restricted Stock Units (RSUs). The award was made on May 15, 2026 and represents a compensation-related acquisition rather than an open‑market trade.
Each RSU represents a contingent right to receive 1 share of Solventum common stock upon settlement. The RSUs are scheduled to fully vest on May 15, 2027, provided Wilson continues to serve through that vesting date. Following this grant, his reported derivative holdings from this award total 3,300 RSUs.
Solventum Corp Chief Human Resources Officer Tammy L. Gomez exercised 3,960 Restricted Stock Units into Common Stock on May 13, 2026. To cover tax obligations, 1,668 shares were disposed of at $74.41 per share, leaving a net 2,292 new shares.
After these transactions, Gomez directly holds 13,362 shares of Common Stock. The related RSUs vest in three equal tranches on May 13, 2025, May 13, 2026, and May 13, 2027, subject to continued service.
Solventum Corp’s Chief Financial Officer Wayde D. McMillan reported routine equity compensation activity involving Restricted Stock Units (RSUs) and common stock. On May 13, 2026, he exercised RSUs covering 9,503 shares of common stock, with no cash exercise price.
To cover tax obligations, 4,404 shares of common stock were disposed of in a tax-withholding transaction at $74.41 per share, which is not an open-market sale. Following these transactions, he directly held 53,041 shares of Solventum common stock and 9,504 RSUs that remain outstanding and continue to vest over time.
Solventum Corp Chief Supply Chain Officer Paul S. Harrington reported routine equity compensation activity involving restricted stock units and related tax withholding. On May 13, 2026, he exercised RSUs to acquire 3,960 shares of Common Stock, with 1,678 shares withheld to cover tax obligations. Following these transactions, he held 22,130 Common Stock shares directly. The RSUs vest in three equal tranches on May 13, 2025, 2026, and 2027, subject to continued service.
Solventum Corp Chief Accounting Officer Mary T. Wilcox reported routine equity compensation activity. She exercised derivative awards covering 2,376 Restricted Stock Units into an equal number of Common Stock shares on May 13, 2026. To cover tax obligations, 728 Common Stock shares were disposed of through a tax-withholding transaction, rather than an open-market sale.
Following these transactions, Wilcox directly holds 6,904 shares of Common Stock and 2,377 Restricted Stock Units. The RSUs are scheduled to vest in three equal tranches on May 13, 2025, May 13, 2026, and May 13, 2027, subject to continued service through each vesting date.
Solventum Corp’s Chief Legal Affairs Officer, Marcela A. Kirberger, reported routine equity compensation activity involving Restricted Stock Units (RSUs) and related tax withholding. She exercised 4,488 RSUs, each converting into one share of common stock at a stated price of $0.00 per share.
To cover tax obligations, 1,952 common shares were disposed of at $74.41 per share as a tax-withholding transaction, not an open-market sale. Following the tax-withholding entry, the Form 4 shows 13,540 common shares reported as directly held.
Solventum Corp Chief Executive Officer Bryan C. Hanson reported routine equity compensation transactions involving company stock. He exercised Restricted Stock Units covering 34,315 shares of Common Stock, increasing his direct holdings. To cover tax obligations, 13,503 shares of Common Stock were disposed of at a price of $74.41 per share through share withholding, not an open-market sale. After these transactions, he directly holds 158,225 shares of Common Stock and 34,316 Restricted Stock Units that continue to vest over time.
Solventum Corp Chief Information Officer Amy Landucci reported routine equity compensation activity involving restricted stock units and related tax withholding. She exercised RSUs to acquire 4,422 shares of Solventum common stock. To cover tax obligations, 2,017 shares were withheld and delivered back as a tax-withholding disposition at $74.41 per share.
After these transactions, Landucci directly owns 41,905 shares of Solventum common stock. The RSUs referenced in the footnotes vest in three equal annual tranches on May 13, 2025, May 13, 2026 and May 13, 2027, contingent on continued service.